Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

Miguel Angel Perales, Izaskun Ceberio, Philippe Armand, Linda J. Burns, Robert Chen, Peter D. Cole, Andrew M. Evens, Ginna G. Laport, Craig H. Moskowitz, Uday Popat, Nishitha M. Reddy, Thomas C. Shea, Julie M. Vose, Jeffrey Schriber, Bipin N. Savani, Paul A. Carpenter

Research output: Contribution to journalReview article

42 Scopus citations


The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma (HL) in pediatric and adult patients is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are included and were reached unanimously by a panel of HL experts. Both autologous and allogeneic HCT offer a survival benefit in selected patients with advanced or relapsed HL and are currently part of standard clinical care. Relapse remains a significant cause of failure after both transplant approaches, and strategies to decrease the risk of relapse remain an important area of investigation.

Original languageEnglish (US)
Pages (from-to)971-983
Number of pages13
JournalBiology of Blood and Marrow Transplantation
Issue number6
Publication statusPublished - Jun 2015



  • Allogeneic transplant
  • Autologous transplant
  • Hematopoietic cell transplantation
  • Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this